Hayley Virgil

Senior Editor, OncLive®
Hayley Virgil heads OncLive's feature article efforts and specializes in social issues and equality in oncology. Prior to joining the company in early 2020, she worked as an editor in numerous industries, including media, marketing, hospitality, and computer science, and freelanced in subjects such as history, culture, and the natural sciences.

Articles

Integration of Clinical Data With Diagnostic Genome Profiling May Produce Personalized Prognostic Predictions in MDS

June 21st 2021

Several distinct subgroups have been identified within the myelodysplastic syndrome genomic landscape and have notable clinical features and discrete evolution patterns that provide proof of concept for next-generation disease classification and prognosis.

Impressive CAR T-Cell Data Point to New Future in Relapsed/Refractory Myeloma

June 21st 2021

C. Ola Landgren, MD, PhD, focuses on the cellular- and immunotherapy-based elements from the event and where these modern therapies optimally fit in multiple myeloma.

Landgren Spotlights Safety Considerations for Carfilzomib Quadruplet in Newly Diagnosed Myeloma

June 17th 2021

C. Ola Landgren, MD, PhD, discusses key safety considerations with a novel carfilzomib quadruplet regimen in patients with newly diagnosed multiple myeloma, the clinical implications of the phase 2 MANHATTAN trial, and next steps for this research.

Hoffman Highlights Key Updates in Rapidly Evolving Multiple Myeloma Care Continuum

June 17th 2021

Quadruplet regimens, such as those with daratumumab, are on the rise in the frontline treatment of patients with multiple myeloma, and the FDA approval of the first BCMA-targeted CAR T-cell therapy idecabtagene vicleucel represents the monumental advance made in the relapsed/refractory setting.

Landgren Lauds Promise of Carfilzomib Quadruplet Regimen in Newly Diagnosed Myeloma

June 16th 2021

C. Ola Landgren, MD, PhD, discusses important research efforts that led to the launch of the phase 2 MANHATTAN trial, the results achieved with the weekly carfilzomib quadruplet regimen in patients with newly diagnosed multiple myeloma, and the potential for this approach irrespective of transplant eligibility status.

Zandelisib/Zanubrutinib Yields Promising Responses in R/R CLL, and B-cell Malignancies

June 11th 2021

A 60 mg dose of zandelisib administered on an intermittent schedule from cycle 1 plus 80 mg of zanubrutinib twice daily yielded promising response rates in patients with relapsed/refractory B-cell malignancies and chronic lymphocytic leukemia.

Lenvatinib Plus Toripalimab and Hepatic Arterial Infusion Chemotherapy May Represent a New First-Line Option in Advanced HCC

June 9th 2021

The addition of toripalimab and hepatic arterial infusion chemotherapy to lenvatinib yielded robust, durable responses in patients with advanced hepatocellular carcinoma, and represents a potential new treatment option for patients in the first line setting.

Mirvetuximab Soravtansine Plus Bevacizumab May Provide an Effective Non-Platinum Option in Recurrent, Platinum Agnostic Ovarian Cancer

June 7th 2021

Mirvetuximab soravtansine in combination with bevacizumab yielded durable responses in patients with recurrent, platinum agnostic ovarian cancer, a population in need of more effective, non-platinum treatments.

Durvalumab Plus Neoadjuvant Chemotherapy Yields Long-Lasting Survival in Early TNBC

June 6th 2021

The addition of durvalumab to neoadjuvant anthracycline and taxane–based chemotherapy was found to significantly improve survival in patients with early triple-negative breast cancer.

Larotrectinib Elicits Robust Responses in TRK Fusion Cancer

June 5th 2021

The highly selective, central nervous system-active TRK inhibitor larotrectinib yielded promising response rates in patients with TRK fusion cancer, including in those with CNS metastases at baseline.

Ponatinib/Blinatumomab Combo Represents Promising Chemo-Free, HSCT-Sparing Treatment for Ph+ ALL

June 4th 2021

The efficacy demonstrated with combination of ponatinib and blinatumomab represent a potentially promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.

Johnson Shines a Light on Racial Disparities in Breast Cancer, Prostate Cancer, and Beyond

June 2nd 2021

Anita Johnson, MD, FACS, discusses existing disparities in cancer, studies that have helped to shed further light on the issue, and ongoing efforts being made to improve outcomes in all patients.

Adjuvant Neoantigen Peptide Vaccine PGV-001 Shows Promise in Multiple Malignancies

June 2nd 2021

A personalized adjuvant neoantigen peptide vaccine, PGV-001, was successfully synthesized and administered to patients across a wide range of malignancies who had a greater than 30% chance of disease recurrence.

Cosibelimab Under Investigation in Metastatic Cutaneous Squamous Cell Carcinoma

June 1st 2021

The anti–PD-L1, fully human monoclonal antibody cosibelimab will be examined in a cohort of patients with metastatic cutaneous squamous cell carcinoma as part of an ongoing phase 1 study.

Vidutolimod/Nivolumab Under Evaluation in PD-1–Refractory Advanced Melanoma

May 30th 2021

The safety and efficacy of the combination of vidutolimod and nivolumab is currently under investigation in patients with PD-1–refractory advanced melanoma.

Uboha Underscores Latest Breakthroughs in Gastrointestinal Cancers

May 28th 2021

Nataliya V. Uboha, MD, PhD, zeros in on the developments with ADCs and monoclonal antibodies in gastric cancer and recent changes in pancreatic cancer as key takeaways from the event.

Eribulin Mesylate Demonstrates Real-World Efficacy in Metastatic Breast Cancer

May 25th 2021

Eribulin mesylate induced favorable responses and improved survival when used as a third or later line of treatment in patients with metastatic breast cancer, including those with triple-negative breast cancer.

Research Efforts Examining Novel Radiation Approaches Flourish at Fox Chase Cancer Center

May 21st 2021

Eric M. Horwitz, MD, FABS, FASTRO, and Stephanie E. Weiss, MD, FASTRO, highlight ongoing research efforts with radiation therapy that are generating excitement at their institution.

Radiation Strategies Blaze a Trail for Better Outcomes in CNS Cancers and Beyond

May 21st 2021

Stephanie E. Weiss, MD, FASTRO and Eric M. Horwitz, MD, FABS, FASTRO, discuss ways to leverage radiation in the treatment of central nervous system metastases, areas of active investigation, and different available strategies that are improving outcomes for patients with cancer.

Relatlimab Plus Nivolumab More Than Doubles PFS in Frontline Advanced Melanoma

May 19th 2021

The addition of relatlimab to nivolumab more than doubled the median progression-free survival compared with nivolumab alone in patients with previously untreated, unresectable or metastatic melanoma.